Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2–negative early breast cancer: a multi-center retrospective study

Fig. 4

Disease-free survival difference between underwent OFS or non-OFS among CR-score>1.42 premenopausal women with HR + HER2- breast cancer. (A) Disease-free survival difference between underwent OFS or non-OFS among CR-score>1.42 premenopausal women with HR + HER2- breast cancer before PSM. (B) Disease-free survival difference between underwent OFS or non-OFS among CR-score>1.42 premenopausal women with HR + HER2- breast cancer after 1:1 PSM. PSM, propensity score matching; HR + HER2-, hormone receptor-positive human epidermal growth factor receptor 2-negative; OFS, ovarian function suppression; CR-score, composite recurrence risk score

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us